Skip Navigation

Treatment of Untreated Acute Myeloid Leukemia

For information about the treatments listed below, see the Treatment Option Overview section.

Standard treatment of untreated acute myeloid leukemia (AML) during the remission induction phase depends on the subtype of AML and may include the following:

  • Combination chemotherapy.
  • Combination chemotherapy with midostaurin, for patients whose AML has a mutation (change) in the FLT3 gene.
  • Combination chemotherapy with gemtuzumab ozogamicin, an antibody-drug conjugate.
  • Intrathecal chemotherapy may be used to treat central nervous system (CNS) leukemia.
  • Supportive care.

For older adults or patients too frail to receive intensive chemotherapy, the following may be continued as long as the patient benefits or until toxic effects occur:

  • Targeted therapy.
  • Low-dose chemotherapy.
  • Targeted therapy with low-dose chemotherapy.
  • Intrathecal chemotherapy may be used to treat CNS leukemia.
  • Supportive care.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

This information is not intended to replace the advice of a doctor. Navigating Care disclaims any liability for the decisions you make based on this information. This information was sourced and adapted from Adapted from the National Cancer Institute's Physician Data Query (PDQ®) Cancer Information Summaries on www.cancer.gov.